MX365325B - Formulación liofilizada de tat-nr2b9c. - Google Patents

Formulación liofilizada de tat-nr2b9c.

Info

Publication number
MX365325B
MX365325B MX2015006784A MX2015006784A MX365325B MX 365325 B MX365325 B MX 365325B MX 2015006784 A MX2015006784 A MX 2015006784A MX 2015006784 A MX2015006784 A MX 2015006784A MX 365325 B MX365325 B MX 365325B
Authority
MX
Mexico
Prior art keywords
nr2b9c
tat
lyophilized formulation
formulations
formulation
Prior art date
Application number
MX2015006784A
Other languages
English (en)
Other versions
MX2015006784A (es
Inventor
Jonathan David Garman
Original Assignee
Nono Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nono Inc filed Critical Nono Inc
Publication of MX2015006784A publication Critical patent/MX2015006784A/es
Publication of MX365325B publication Critical patent/MX365325B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a formulaciones liofilizadas de agentes activos, particularmente de TAT NR2B9c. TAT-NR2B9c ha mostrado promesa para tratar apoplejía, aneurisma, hemorragia subaracnoidea y otras condiciones neurológicas o neurotraumáticas. Estas formulaciones son estables a temperatura ambiente facilitando de este modo el mantenimiento de suministros de esta formulación en ambulancias para la administración en la escena de la enfermedad o accidente o en tránsito a un hospital.
MX2015006784A 2012-11-28 2013-11-25 Formulación liofilizada de tat-nr2b9c. MX365325B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261730952P 2012-11-28 2012-11-28
PCT/US2013/071755 WO2014085349A1 (en) 2012-11-28 2013-11-25 Lyophilized formulation of tat-nr2b9c

Publications (2)

Publication Number Publication Date
MX2015006784A MX2015006784A (es) 2015-10-29
MX365325B true MX365325B (es) 2019-05-29

Family

ID=50828392

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006784A MX365325B (es) 2012-11-28 2013-11-25 Formulación liofilizada de tat-nr2b9c.

Country Status (19)

Country Link
US (1) US20140162957A1 (es)
EP (1) EP2925338B8 (es)
JP (1) JP6427104B2 (es)
KR (1) KR102166374B1 (es)
CN (2) CN109106941A (es)
AU (1) AU2013352437B2 (es)
CA (1) CA2892965C (es)
DK (1) DK2925338T3 (es)
ES (1) ES2725598T3 (es)
HK (1) HK1215793A1 (es)
HR (1) HRP20190707T1 (es)
HU (1) HUE043820T2 (es)
LT (1) LT2925338T (es)
MX (1) MX365325B (es)
PL (1) PL2925338T3 (es)
PT (1) PT2925338T (es)
SI (1) SI2925338T1 (es)
TR (1) TR201905787T4 (es)
WO (1) WO2014085349A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
CN106661126B (zh) 2014-05-28 2021-12-10 诺诺公司 TAT-NR2B9c的氯盐
US10206878B2 (en) 2014-05-28 2019-02-19 Nono Inc. Lyophilized formulation of TAT-NR2B9C with acetylation scavenger
EP3247400A1 (en) * 2015-01-18 2017-11-29 Biogen MA Inc. Formulations and screening of biological therapeutic agents
KR20180135493A (ko) * 2016-04-27 2018-12-20 바이오셀즈(베이징) 바이오테크 코., 엘티디. 흥분성 신경독성 관련 손상의 치료 방법
CN106619170A (zh) * 2016-10-26 2017-05-10 暨南大学 包含stp和生长因子的活性组合物及其化妆品或护肤品
CN110627877A (zh) * 2019-09-25 2019-12-31 成都奥达生物科技有限公司 一种psd-95抑制剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605884A (en) * 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
CA2551190A1 (en) * 2003-12-23 2005-07-07 Nono Inc. Polypeptides for modulating binding of trp channel proteins and trp-associated proteins.
GB0329918D0 (en) * 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
WO2007002395A1 (en) * 2005-06-23 2007-01-04 Arbor Vita Corporation Methods and compositions for modulating cox
US8633160B2 (en) * 2005-12-30 2014-01-21 Nono Inc. Small molecule inhibitors of PDZ interactions
CA2651348A1 (en) * 2006-05-05 2007-11-15 Transtech Pharma, Inc. Rage fusion proteins, formulations, and methods of use thereof
EP1884521A1 (en) * 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
US8933013B2 (en) * 2007-12-05 2015-01-13 Nono Inc. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
WO2010028089A2 (en) * 2008-09-03 2010-03-11 Arbor Vita Corporation Agents and methods for treatment of pain
US8099602B2 (en) * 2008-09-26 2012-01-17 Mykonos Software, Inc. Methods for integrating security in network communications and systems thereof
PL2440230T3 (pl) * 2009-06-10 2021-06-14 Nono Inc. Schematy leczenia do leczenia choroby neurologicznej
WO2012021854A2 (en) * 2010-08-12 2012-02-16 Nono, Inc. Treatment of penetrative injury to the brain

Also Published As

Publication number Publication date
AU2013352437B2 (en) 2018-04-12
MX2015006784A (es) 2015-10-29
EP2925338A1 (en) 2015-10-07
EP2925338A4 (en) 2016-05-25
SI2925338T1 (sl) 2019-09-30
CN109106941A (zh) 2019-01-01
AU2013352437A1 (en) 2015-07-09
ES2725598T3 (es) 2019-09-25
EP2925338B1 (en) 2019-03-27
LT2925338T (lt) 2019-05-10
HUE043820T2 (hu) 2019-09-30
DK2925338T3 (da) 2019-05-06
WO2014085349A1 (en) 2014-06-05
KR102166374B1 (ko) 2020-10-15
PT2925338T (pt) 2019-05-31
HRP20190707T1 (hr) 2019-10-04
CA2892965A1 (en) 2014-06-05
CN105101986B (zh) 2018-09-25
HK1215793A1 (zh) 2016-09-15
BR112015012422A2 (pt) 2017-09-12
JP2016502537A (ja) 2016-01-28
CN105101986A (zh) 2015-11-25
KR20150094656A (ko) 2015-08-19
US20140162957A1 (en) 2014-06-12
CA2892965C (en) 2021-06-01
PL2925338T3 (pl) 2019-11-29
JP6427104B2 (ja) 2018-11-21
TR201905787T4 (tr) 2019-05-21
EP2925338B8 (en) 2019-05-22

Similar Documents

Publication Publication Date Title
MX365325B (es) Formulación liofilizada de tat-nr2b9c.
MX2020009633A (es) Sal de cloruro de tat-nr2b9c.
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
MY170671A (en) Glucagon analogues
MX2019003249A (es) Diagnostico, prevencion y tratamiento de enfermedades de la articulacion.
BR112013008601A8 (pt) Formulações de emulsão de clevidipina contendo agentes antimicrobianos
MX2014010537A (es) Moduladores de receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dermicas.
DK3479863T3 (da) Sammensætninger, fremgangsmåder og artikler indeholdende farmaceutisk nitrogenoxid og regulerede leveringssystemer deraf til patienter
CO7151509A2 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
PH12014501866A1 (en) Thermosensitive nanoparticle formulations and method of making the same
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
TR201004464A2 (tr) Kemik erimesi için formülasyon.
EP2886112A4 (en) COMPOSITION CONTAINING AS ACTIVE INGREDIENT OF S-ALLYL-L-CYSTEINE FOR PREVENTING OR TREATING OCULAR DISEASES, AND PHARMACEUTICAL FORMULATION COMPRISING THE SAME
EP2870964A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF COLITIET COMPRISING S-ALLYL-L-CYSTEINE AS ACTIVE INGREDIENT AND MEDICAL PREPARATION COMPRISING THE SAME
MX2012014071A (es) Composicion farmaceutica estable para el tratamiento de osteoporosis.
MX2013002295A (es) 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2015014905A (es) Compuestos de pirazino - [1,2-a] indol, su preparacion y su uso en medicamentos.
TR201100151A2 (tr) İbandronate formülasyonu.
ZA201204070B (en) Prophylactic or therapeutic agent for crohn's disease comprising organic acid polymer as active ingredient
CA2860159C (en) Peptides targeting receptor activator of nuclear factor-kappa b (rank) and their applications
TN2014000444A1 (en) INTRAUTERINE APPLICATION OF 18-METHYL-15β,16β-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONE SYSTEMS, INTRAUTERINE SYSTEMS CONTAINING 18-METHYL-15SS,16SS-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONE, AS WELL AS THE USE THEREOF IN CONTRACEPTION AND GYNAECOLOGICAL THERAPY
PH12015502420A1 (en) PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS
WO2013168179A3 (en) Controlled release pharmaceutical formulations of antiviral agents
WO2013127539A3 (de) Pharmazeutische formulierung enthaltend flupirtin

Legal Events

Date Code Title Description
FG Grant or registration